Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer

The companion diagnostic test for checkpoint inhibitor immune therapy is an immunohistochemical test for PD-L1. The test has been shown to be reproducible for expression in tumor cells, but not in immune cells. Immune cells were used in the IMpassion130 trial which showed PD-L1 expression was associ...

Descripción completa

Detalles Bibliográficos
Autores principales: Rimm, David L., Han, Gang, Taube, Janis M., Yi, Eunhee S., Bridge, Julia A., Flieder, Douglas B., Homer, Robert, Roden, Anja C., Hirsch, Fred R., Wistuba, Ignacio I., Pusztai, Lajos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567382/
https://www.ncbi.nlm.nih.gov/pubmed/31196152
http://dx.doi.org/10.1186/s13058-019-1156-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567382/
https://www.ncbi.nlm.nih.gov/pubmed/31196152
http://dx.doi.org/10.1186/s13058-019-1156-6

Ejemplares similares